Vaccine formulations that enhance Th1 levels and CD8+ T-cell responses are highly sought after as they are effective for immunization against pathogens for which there are no currently licensed vaccines (examples: HIV-AIDS, malaria, and tuberculosis) [66]. The gene discussed is CD8A; the disease is malaria.